According to a market report by Lucintel, the future of the global neuropathic pain drug market looks promising with opportunities in the hospital pharmacy, drugs store & retail pharmacy, and online pharmacy markets. The global neuropathic pain drug market is expected to reach an estimated $10 billion by 2030 from $8 billion in 2024 at a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are the increasing cases of spinal stenosis and diabetic neuropathy, as well as the rise in initiatives undertaken by various government associations to enhance awareness.
A more
than 150-page report to understand trends, opportunity and forecast in global neuropathic
pain drug market to 2030 by drug class (antidepressants, anticonvulsant,
opioids, capsaicin, and others), indication (diabetic neuropathy, spinal
stenosis, chemotherapy-induced peripheral neuropathy, and others), distribution
channel (hospital pharmacies, drugs stores and retail pharmacies, and online
pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of
the World).
Lucintel
forecasts that, within the drug class category, anticonvulsant is expected to
witness the highest growth over the forecast period due to widespread
acceptance of anticonvulsant drugs for managing neuropathic pain.
Within the
distribution channel category, drug stores and retail pharmacies will remain
the largest segment due to convenience in shopping being amplified by the surge
in e-commerce sales, enhancements in logistics services, and the ease of
payment options.
Download
sample by clicking on neuropathic
pain drug market.
In terms
of regions, North America is expected to witness the highest growth over the
forecast period due to the existence of numerous significant players in the
field.
Pfizer,
Eli Lilly and Company, Novartis, Mallinckrodt Pharmaceuticals, Glenmark
Pharmaceuticals Limited, Teva Pharmaceuticals, Sun Pharmaceutical Industries are
the major suppliers in the neuropathic
pain drug market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment